News

The VRBPAC voted 16-2 against the booster dose because of unclear evidence regarding the need.

The potential number of adults projected to be newly eligible for treatment had a range from 643,161 (LVEF, 41% - 50%) to 1,838,756 (LVEF, 41% - 60%).

The US Pain Foundation starts off September strong for Pain Awareness Month by releasing a touching video that gets personal about chronic pain.

The machine learning model outperformed a comparison logistic regression model in identifying high-risk patients for HBV.

As predicted, previous asthma during early childhood was a strong risk factor for asthma in young adulthood.

Most of Europe lacks an active and coordinated surveillance plan in place for monitoring hospital-acquired CDI.

Investigators report that few medical schools in Europe consider allergology to be an important area of study, resulting in a lack of knowledge regarding certain allergy practices.

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

Patients with chronic pain may benefit from rotation to buprenorphine.

Hospitals that use the 3-dose vaccine would spend approximately 37% more on prophylaxis for hepatitis B.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

The evidence regarding patients with entecavir-treated chronic hepatitis B without maintaining virological response is limited and uncertain.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Voxelotor has the potential to decrease long-term problems in pediatric sickle cell disease.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

The new PDUFA date for Nefecon will be December 15, 2021.

An expert considers the buildup of cardiovascular and cardiometabolic innovation, and the role of regulatory delays in it.

Kim Smith-Whitley, MD, discussed her research on voxelotor as treatment for children with sickle cell disease.

CDI rates remained down in 2020 despite an increase in antibiotic use during the pandemic.

Anxiety, social support, mother-infant relationship, and infant temperament all improved after a 1-day CBT-based workshop.

Co-infections of HBV and HIV often lead to an increased risk of overall mortality.

How inclisiran, bempedoic acid, and other investigative therapies may contribute to cardiometabolic disease management.

Voxelotor study results show it’s just as effective in children as adults and adolescents.

Dr. Amar Deshpande said more safety studies are needed before examining whether multiple biologics can be used to treat IBD.

A discussion on the winning qualities of the CARDIA study, and why it's also hard to replicate.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.